CBLI Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (1 Sep 2021 @ 00:00):

Stats
Today's Volume	116 255
Average Volume	156 953
Market Cap	226.39M
EPS	$-0.0426 ( 2021-08-16 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0.436 (13.75%)

Insider Trading

Date	Person	Action	Amount	type
2021-07-27	Selsky Clifford	Buy	101 579	Common Stock, par value $0.005 per share
2021-07-27	Aronstam Peter	Buy	141 370	Common Stock, par value $0.005 per share
2021-07-27	Selsky Clifford	Buy	0
2021-07-27	Aronstam Peter	Buy	0
2021-07-27	Barbarick Steve K	Buy	0

INSIDER POWER
0.00
Last 91 transactions
Buy: 2 702 906 \| Sell: 404 086

Volume Correlation

Long: 0.15 (neutral)

Short: -0.89 (strong negative)

Signal:(40.963) Neutral

Cleveland Biolabs Inc Correlation

10 Most Positive Correlations
HIBB	0.941
BEAT	0.933
HALO	0.926
BMRA	0.926
EMKR	0.925
VLCN	0.924
FNWD	0.912
PROV	0.911
GCBC	0.91
NDLS	0.909

10 Most Negative Correlations
GPACU	-0.931
RXST	-0.928
MSAC	-0.926
TZPS	-0.925
KAII	-0.923
FRBN	-0.92
META	-0.919
MLAI	-0.919
ALPA	-0.916
AEAC	-0.916

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Cleveland Biolabs Inc Correlation - Currency/Commodity

-0.45
( neutral )

-0.35
( neutral )

-0.59
( weak negative )

0.77
( moderate )

-0.24
( neutral )

0.06
( neutral )

Cleveland Biolabs Inc Financials

Annual	2020
Revenue:	$262 942
Gross Profit:	$262.94 (0.10 %)
EPS:	$-0.190

Q2	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-0.0426

Q1	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-0.0400

Q4	2020
Revenue:	$0.00
Gross Profit:	$0.00 (100.00 %)
EPS:	$-0.0534

Financial Reports:

No articles found.

Cleveland Biolabs Inc

Cleveland BioLabs, Inc. operates as a biopharmaceutical company, which engages in the research and development of drugs. The company is headquartered in Buffalo, New York and currently employs 15 full-time employees. The firm is engaged in developing approaches to activate the immune system and address serious medical needs. Its platform of Toll-like immune receptor activators has applications in mitigation of radiation injury and immuno-oncology. Its advanced product candidate is Entolimod, an immuno-stimulatory agent, which it is developing as a radiation countermeasure and an immunotherapy for oncology and other indications. Its other products include CBLB612, Mobilan and CBL0137. CBLB612 is a compound based upon a natural activator of another tissue-specific component of the innate immune system, the toll-like receptor 2 (TLR2)/ toll-like receptor 6 (TLR6) heterodimeric receptor. Mobilan is a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand. CBL0137 is a small molecule with a multi-targeted mechanism of action that may be useful for the treatment of various types of cancer.